Jocelyn Chapman, MD

Title(s)Associate Professor, Ob/Gyn, Reproductive Sciences
SchoolSchool of Medicine
Address490 Illinois Street, #10125
San Francisco CA 94158
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Next-generation sequencing technologies developed in the last ten years have dramatically widened our view into the many kinds of events that are driving tumor biology. Gene fusions, copy number alterations, mutations, epigenetic changes and transcript level alterations can all be ascertained via the knife of DNA and RNA sequencing. Single cell sequencing of early cancer and molecular testing of circulating blood will allow us to better understand the pathogenesis of early cancer and discover early molecular changes that may allow for an early detection test for ovarian cancer. Statistical methods, factor analysis, insights from evolutionary biology and an understanding of mutation processes at work in early cancer can help us distill out the important driver events and give us useful insights into the processes driving tumor evoluation.

    I am specifically interested in using these integrated approaches to help understand the early events in the pathogenesis of ovarian, fallopian tube and peritoneal cancer (ovarian cancer) to improve our understanding of the development of this disease and to find novel ways of early detection. New discoveries regarding the carcinogenesis of BRCA-associated ovarian cancer have illuminated an opportunity to detect early-stage disease using molecular signals in circulation. As such, I have developed a prospective clinical trial to test whether detection of these molecular changes can predict early ovarian cancer and I am collaborating with clinicians and scientists across disciplines and across institutions with a goal to further our understanding of the early events in pelvic HGSC.

    My clinical research interests involve optimizing the rational and economical delivery of medical care to our gynecologic oncology patients. To this end, we have piloted the successful implementation of clinical pathways to reduce hospital stays post-operatively. Such process improvement involves multi-disciplinary efforts and cross-discipline collaboration. Our current efforts are focused at improving the patient education experience related to peri-operative care in partnership with our Gynecologic Oncology nursing team. Previous process improvements have involved implementing post-operative immunonutrition with a demonstrable reduction in post-operative wound complications and implementation of post-surgical pathways with a demonstrable reduction in hospital length of stay.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 Jun; 8:e2300494. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. PMID: 38865673.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    2. Evidence-based prescribing of opioids after laparotomy: A quality-improvement initiative in gynecologic oncology. Gynecol Oncol Rep. 2024 Jun; 53:101396. Kay AH, Levy R, Hills N, Jang A, Mcgough-Maduena A, Dematteo N, Mark M, Ueda S, Chen LM, Chapman JS. PMID: 38725997; PMCID: PMC11078636.
      View in: PubMed   Mentions:
    3. Exploring the relationship between language, postoperative pain, and opioid use. AJOG Glob Rep. 2024 May; 4(2):100342. Levy RA, Kay AH, Hills N, Chen LM, Chapman JS. PMID: 38681953; PMCID: PMC11046298.
      View in: PubMed   Mentions:
    4. Roadmap to safety: a single center study of evidence-informed approach to placenta accreta spectrum. Front Surg. 2024; 11:1347549. Levy RA, Diala PC, Rothschild HT, Correa J, Lehrman E, Markley JC, Poder L, Rabban J, Chen LM, Gras J, Sobhani NC, Cassidy AG, Chapman JS. PMID: 38511075; PMCID: PMC10950927.
      View in: PubMed   Mentions:
    5. The past, present, and future of opioid prescribing: Perioperative opioid use in gynecologic oncology patients after laparotomy at a single institution from 2012 to 2021. Gynecol Oncol Rep. 2023 Apr; 46:101172. Kay AH, Othieno A, Boscardin J, Chen LL, Alvarez EA, Swanson M, Ueda S, Chen LM, Chapman JS. PMID: 37065538; PMCID: PMC10090236.
      View in: PubMed   Mentions:
    6. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol Oncol. 2022 11; 167(2):334-341. Hou JY, Chapman JS, Kalashnikova E, Pierson W, Smith-McCune K, Pineda G, Vattakalam RM, Ross A, Mills M, Suarez CJ, Davis T, Edwards R, Boisen M, Sawyer S, Wu HT, Dashner S, Aushev VN, George GV, Malhotra M, Zimmermann B, Sethi H, ElNaggar AC, Aleshin A, Ford JM. PMID: 36117009.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    7. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022 01 06; 185(1):184-203.e19. Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. PMID: 34963056; PMCID: PMC8862608.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    8. Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Gynecol Oncol. 2022 02; 164(2):348-356. Korenaga TK, Yoshida EJ, Pierson W, Chang J, Ziogas A, Swanson ML, Chapman JS, Sinha S, Chen LM. PMID: 34865860.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    9. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol Rep. 2021 Nov; 38:100870. McNamara B, Guerra R, Qin J, Craig AD, Chen LM, Varma MG, Chapman JS. PMID: 34646929; PMCID: PMC8496105.
      View in: PubMed   Mentions:
    10. Primary treatment of advanced ovarian cancer: how does the 'real world' practice? Future Oncol. 2021 Dec; 17(34):4687-4696. Craig AD, Garcia E, Peters PN, Chen LM, Chapman JS. PMID: 34435878.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    11. PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer. Abdom Radiol (NY). 2021 01; 46(1):341-350. Peters PN, Pierson WE, Chen LM, Westphalen AC, Chapman JS, Hsu IC. PMID: 32638077.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    12. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020 04; 157(1):55-61. Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, Chapman JS. PMID: 32139151.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    13. Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology. Gynecol Oncol. 2019 10; 155(1):93-97. Ahmad TR, Chen LM, Chapman JS, Chen LL. PMID: 31492539.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    14. Inflammatory Myofibroblastic Tumor Associated With the Placenta: Short Tandem Repeat Genotyping Confirms Uterine Site of Origin. Am J Surg Pathol. 2018 06; 42(6):807-812. Ladwig NR, Schoolmeester JK, Weil L, Chapman JS, Zaloudek C, Umetsu SE. PMID: 29505427.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    15. Disparities in genetics assessment for women with ovarian cancer: Can we do better? Gynecol Oncol. 2018 04; 149(1):84-88. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM. PMID: 29605055.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    16. PET/MR Imaging in Gynecologic Oncology. Magn Reson Imaging Clin N Am. 2017 Aug; 25(3):667-684. Ohliger MA, Hope TA, Chapman JS, Chen LM, Behr SC, Poder L. PMID: 28668166.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    17. In Reply. Obstet Gynecol. 2017 01; 129(1):208. Chen LM, Chen LL, Chapman JS. PMID: 28002298.
      View in: PubMed   Mentions:    Fields:    
    18. Genomic insights in gynecologic cancer. Curr Probl Cancer. 2017 Jan - Feb; 41(1):8-36. Roddy E, Chapman J. PMID: 28088330.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    19. Enhanced Recovery Pathways for Improving Outcomes After Minimally Invasive Gynecologic Oncology Surgery. Obstet Gynecol. 2016 07; 128(1):138-144. Chapman JS, Roddy E, Ueda S, Brooks R, Chen LL, Chen LM. PMID: 27275797.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    20. Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course". J Natl Compr Canc Netw. 2016 Mar; 14(3):lxvi-lxviii. Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS. PMID: 26957621.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. The Authors Respond. J Natl Compr Canc Netw. 2016 Mar; 14(3):lxviii. Chapman JS, Collisson EA, Taylor BS. PMID: 27396027.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nat Biotechnol. 2016 Feb; 34(2):155-63. Chang MT, Asthana S, Gao SP, Lee BH, Chapman JS, Kandoth C, Gao J, Socci ND, Solit DB, Olshen AB, Schultz N, Taylor BS. PMID: 26619011; PMCID: PMC4744099.
      View in: PubMed   Mentions: 403     Fields:    Translation:Humans
    23. Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course. J Natl Compr Canc Netw. 2015 Jul; 13(7):835-45. Chapman JS, Asthana S, Cade L, Chang MT, Wang Z, Zaloudek CJ, Ueda S, Collisson EA, Taylor BS. PMID: 26150578.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Post-operative enteral immunonutrition for gynecologic oncology patients undergoing laparotomy decreases wound complications. Gynecol Oncol. 2015 Jun; 137(3):523-8. Chapman JS, Roddy E, Westhoff G, Simons E, Brooks R, Ueda S, Chen L. PMID: 25888979.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    25. Managing symptoms and maximizing quality of life after preventive interventions for cancer risk reduction. Curr Opin Obstet Gynecol. 2015 Feb; 27(1):40-4. Chapman JS, Jacoby V, Chen LM. PMID: 25502430.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    26. Routine bimanual pelvic examinations: practices and beliefs of US obstetrician-gynecologists. Am J Obstet Gynecol. 2013 Feb; 208(2):109.e1-7. Henderson JT, Harper CC, Gutin S, Saraiya M, Chapman J, Sawaya GF. PMID: 23159688; PMCID: PMC4350675.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    27. Surveillance of survivors: follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecol Oncol. 2011 Aug; 122(2):339-43. Chapman JS, Powell CB, McLennan J, Crawford B, Mak J, Stewart N, Chen LM. PMID: 21531449.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    28. H1N1 influenza in pregnancy: cause for concern. Obstet Gynecol. 2009 Oct; 114(4):885-891. Saleeby E, Chapman J, Morse J, Bryant A. PMID: 19888049.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    29. Neurodevelopmental outcomes of congenital diaphragmatic hernia survivors followed in a multidisciplinary clinic at ages 1 and 3. J Pediatr Surg. 2008 Jun; 43(6):1035-43. Friedman S, Chen C, Chapman JS, Jeruss S, Terrin N, Tighiouart H, Parsons SK, Wilson JM. PMID: 18558179.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    30. Long-term functional impact of congenital diaphragmatic hernia repair on children. J Pediatr Surg. 2007 Apr; 42(4):657-65. Chen C, Jeruss S, Chapman JS, Terrin N, Tighiouart H, Glassman E, Wilson JM, Parsons SK. PMID: 17448762.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    Jocelyn's Networks
    Concepts (171)
    Derived automatically from this person's publications.
    Co-Authors (54)
    People in Profiles who have published with this person.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department